This article was originally published in The Tan Sheet
Executive SummaryLeaflets on drugs currently provided to patients do not provide information they value and find useful, according to researchers. In Health Technology Assessment, D.K. Raynor, Pharmacy Practice and Medicines Management Group, University of Leeds School of Healthcare, U.K., et al., say most people do not value written information they receive about drugs. Patients want to know about possible adverse events and require information to help decide whether to take a medicine. "The readability of medicines' information is important to patients, with concerns about complex language and poor visual presentation," Raynor et al. say. They included 64 papers after conducting a database search and tabulating results...
You may also be interested in...
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.
Bioresearchers at the Centers for Disease Control and Prevention are hoping that diagnostic platforms previously used to develop tests for outbreaks of other epidemic respiratory diseases, including SARS and MERS, can be built on to develop new diagnostics to detect more cases in the current coronavirus outbreak, US infectious disease authorities say. This comes as more patients are monitored around the US for the disease, and a Chicago woman returning from China tests positive.